Results 61 to 70 of about 26,042 (243)
Maxillofacial Plastic and Reconstructive Surgery, 2017 Background Imatinib mesylate is an inhibitor of the tyrosine kinase Bcr–Abl and a first-line treatment for Philadelphia chromosome-positive chronic myeloid leukaemia (CML).
Gian Paolo Bombeccari +6 more
doaj +1 more source
Clinical and Translational Science, Volume 18, Issue 10, October 2025.ABSTRACT Rare diseases affect a small population of patients, resulting in low incentives for developing orphan drug products (ODPs). The United States Congress passed the Orphan Drug Act of 1983 to incentivize pharmaceutical manufacturers to develop drugs to treat rare diseases.
Robert Hopefl +6 more
wiley +1 more source
Monitoring Twenty-Six Chronic Myeloid Leukemia Patients by BCR-ABL mRNA Level in Bone Marrow: A Single Hospital Experience [PDF]
, 2011 Chronic myeloid leukemia (CML) is caused by the BCR-ABL oncogene. The Philadelphia chromosome (Ph) from a reciprocal translocation, t(9;22) (q34;q11) causes a fusion gene, BCR-ABL, that encodes a constitutively active tyrosine kinase. Treatment of CML by
Akagi, Tomoaki +9 more
core +1 more source
The Journal of Physiology, Volume 603, Issue 19, Page 5273-5297, October 1, 2025.Abstract figure legend Fibro/adipogenic progenitors (FAPs) are cells resident in the muscle (skeletal and cardiac) niche. FAPs are active participants in the process of muscle degeneration in cardiovascular and neuromuscular diseases. Here, the accumulation of fatty and fibrous tissue is a hallmark.
Elisa Villalobos +2 more
wiley +1 more source
Prenatal Diagnosis, Volume 45, Issue 10, Page 1334-1342, September 2025.ABSTRACT Cytogenetic technologies such as G‐banding chromosome and FISH analyses have long been the gold standard diagnostic test in prenatal genetic testing. However, unbiased next‐generation sequencing technologies such as fetal exome or genome sequencing (ES/GS) are becoming widely accessible and increasingly utilized, particularly for fetuses with ...
Yassmine M. N. Akkari +2 more
wiley +1 more source
Association of differential gene expression with imatinib mesylate and omacetaxine mepesuccinate toxicity in lymphoblastoid cell lines [PDF]
, 2012 BackgroundImatinib mesylate is currently the drug of choice to treat chronic myeloid leukemia. However, patient resistance and cytotoxicity make secondary lines of treatment, such as omacetaxine mepesuccinate, a necessity.
Blangero, John +7 more
core +2 more sources
Another Look at Imatinib Mesylate
New England Journal of Medicine, 2007 Mark W.M. Schellings +2 more
openalex +5 more sources
Andrology, Volume 13, Issue 6, Page 1575-1591, September 2025.Abstract Background Imatinib and dasatinib are tyrosine kinase inhibitors (TKIs) increasingly used to treat several diseases in both children and adults at fertile age. We have previously shown that imatinib has adverse effects on developing testis, and imatinib‐treated male patients have been reported to have reduced sperm counts.
Anna Eggert +10 more
wiley +1 more source
Journal of Cosmetic Dermatology, Volume 24, Issue 9, September 2025.ABSTRACT Background Patients treated with cancer therapies often experience changes in physical appearance, body image perception, and self‐esteem, which influence their quality of life (QoL). Aims To assess the effect of treatment with hyaluronic acid (HA) dermal fillers on QoL, safety, and perceived skin changes of oncology patients. Methods A single‐
Eden Bar +8 more
wiley +1 more source
Pretreatment with VEGF(R)-inhibitors reduces interstitial fluid pressure, increases intraperitoneal chemotherapy drug penetration, and impedes tumor growth in a mouse colorectal carcinomatosis model [PDF]
, 2015 Cytoreductive surgery combined with intraperitoneal chemotherapy (IPC) is currently the standard treatment for selected patients with peritoneal carcinomatosis of colorectal cancer.
Ceelen, Wim +6 more
core +4 more sources